Belite Bio, Inc (BLTE)
Nasdaq: BLTE · Pharmaceutical Preparations · San Diego, CA · filing with the SEC since 2021
Who runs Belite Bio, Inc
Officers and directors as they report to the SEC on Forms 3, 4 and 5, named as filedChief executive, as filed
Lin Yu-Hsin
Chief Executive Officer. First filing Mar 2026, latest Oct 30, 2026, 3 filings in all.
Officers reporting now
4
of 9 people with a filing in the last fifteen months
Directors reporting now
5
9 people on the record since 2026
Officerssales are open-market, Oct 30, 2025 to Oct 30, 2026
| Name | Title as filed | First filing | Latest filing | Sales, 12 months |
|---|---|---|---|---|
| Lin Yu-Hsin | Chief Executive Officer | Mar 2026 | Oct 30, 2026 | 25 · $20.8M |
| Chuang Hao-Yuan | Chief Financial Officer | Mar 2026 | Oct 30, 2026 | 25 · $14.0M |
| Scholl Hendrik Peter | Chief Medical Officer | Mar 2026 | Oct 5, 2026 | 21 · $2.9M |
| Mata Nathan L. | Chief Scientific Officer | Mar 2026 | May 8, 2026 | 103 · $2.7M |
Directorssales are open-market, Oct 30, 2025 to Oct 30, 2026
| Name | Role | First filing | Latest filing | Sales, 12 months |
|---|---|---|---|---|
| Chen Wan-Shan | director | Mar 2026 | Oct 30, 2026 | 1 · $200,000 |
| Biddle Gary Clark | director | Mar 2026 | Mar 18, 2026 | none |
| Chen Xiao-Hui | director | Mar 2026 | Mar 18, 2026 | none |
| Longo John Michael | director | Mar 2026 | Mar 18, 2026 | none |
| Lu Ita | director | Mar 2026 | Mar 18, 2026 | none |
A person is listed as reporting now after a filing in the last fifteen months. The record shows when someone last filed; it does not say why they stopped. Each name links to the filings on sec.gov.